BACKGROUND: Success of chemotherapy and alleviation of pain are frequently less than optimal in pancreatic cancer patients, leading to increasing interest in new pharmacological substances, such as vanilloids. Our study addressed the question of whether vanilloids influence pancreatic cancer cell growth, and if vanilloids could be used for pain treatment via the vanilloid 1 receptor (VR1) in pancreatic cancer patients. METHODS: In vitro, the effect of resiniferatoxin (vanilloid analogue) on apoptosis and cell growth in pancreatic cancer cells--either alone, combined with 5-fluorouracil (5-FU), or combined with gemcitabine--was determined by annexin V staining, FACS analysis, and MTT assay, respectively. VR1 expression was evaluated on RNA and protein level by quantitative polymerase chain reaction and immunohistochemistry in human pancreatic cancer and chronic pancreatitis. Patient characteristics--especially pain levels--were registered in a prospective database and correlated with VR1 expression. RESULTS: Resiniferatoxin induced apoptosis by targeting mitochondrial respiration and decreased cell growth in pancreatic cancer cells without showing synergistic effects with 5-FU or gemcitabine. Expression of VR1 was significantly upregulated in human pancreatic cancer and chronic pancreatitis. VR1 expression was related to the intensity of pain reported by cancer patients but not to the intensity of pain reported by patients with chronic pancreatitis. CONCLUSIONS: Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer. Furthermore, vanilloid might be a novel and effective treatment option for neurogenic pain in patients with pancreatic cancer.
BACKGROUND: Success of chemotherapy and alleviation of pain are frequently less than optimal in pancreatic cancerpatients, leading to increasing interest in new pharmacological substances, such as vanilloids. Our study addressed the question of whether vanilloids influence pancreatic cancer cell growth, and if vanilloids could be used for pain treatment via the vanilloid 1 receptor (VR1) in pancreatic cancerpatients. METHODS: In vitro, the effect of resiniferatoxin (vanilloid analogue) on apoptosis and cell growth in pancreatic cancer cells--either alone, combined with 5-fluorouracil (5-FU), or combined with gemcitabine--was determined by annexin V staining, FACS analysis, and MTT assay, respectively. VR1 expression was evaluated on RNA and protein level by quantitative polymerase chain reaction and immunohistochemistry in humanpancreatic cancer and chronic pancreatitis. Patient characteristics--especially pain levels--were registered in a prospective database and correlated with VR1 expression. RESULTS:Resiniferatoxin induced apoptosis by targeting mitochondrial respiration and decreased cell growth in pancreatic cancer cells without showing synergistic effects with 5-FU or gemcitabine. Expression of VR1 was significantly upregulated in humanpancreatic cancer and chronic pancreatitis. VR1 expression was related to the intensity of pain reported by cancerpatients but not to the intensity of pain reported by patients with chronic pancreatitis. CONCLUSIONS:Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of humanpancreatic cancer. Furthermore, vanilloid might be a novel and effective treatment option for neurogenic pain in patients with pancreatic cancer.
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Bodo Schniewind; Matthias Christgen; Roland Kurdow; Sieglinde Haye; Bernd Kremer; Holger Kalthoff; Hendrik Ungefroren Journal: Int J Cancer Date: 2004-03-20 Impact factor: 7.396
Authors: Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Daniel Broderick Longley; Wendy Louise Allen; Ultan McDermott; Timothy Richard Wilson; Tariq Latif; John Boyer; Maria Lynch; Patrick Gerard Johnston Journal: Clin Cancer Res Date: 2004-05-15 Impact factor: 12.531
Authors: Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko Journal: ChemMedChem Date: 2015-10-05 Impact factor: 3.466
Authors: Cara B Gonzales; Nameer B Kirma; Jorge J De La Chapa; Richard Chen; Michael A Henry; Songjiang Luo; Kenneth M Hargreaves Journal: Oral Oncol Date: 2014-01-14 Impact factor: 5.337
Authors: Aura A J van Esch; Mark P Lamberts; René H M te Morsche; Martijn G H van Oijen; Jan B M J Jansen; Joost P H Drenth Journal: BMC Gastroenterol Date: 2009-12-24 Impact factor: 3.067